Clinical Trial Update: Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 study evaluating antibody responses to a tetravalent meningococcal conjugate vaccine (A, C, Y, W-135) in healthy adults; the trial was terminated and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Meningitis
• Meningococcemia

Drugs mentioned

• Meningococcal A, C, Y, W-135 conjugate vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcemia | Phase 2 | Status: TERMINATED | Results posted: 2009-04-27